Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31

AVANOS MEDICAL, INC.

2025-Q2 EPS reported -$1.52 revenue$342,500,000

Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.
Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.
Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.
Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.
Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.